Details for Patent: 11,046,674
✉ Email this page to a colleague
Which drugs does patent 11,046,674 protect, and when does it expire?
Patent 11,046,674 protects FRUZAQLA and is included in one NDA.
This patent has forty-nine patent family members in thirty-six countries.
Summary for Patent: 11,046,674
| Title: | Crystalline forms of 6-((6,7-dimethoxyquinazolin-4-yl)oxy)-N,2-dimethylbenzofuran-3-carboxamide |
| Abstract: | Crystalline forms of compound 6-(6,7-dimethoxyquinazolin-4-yloxy)-N,2-dimethylbenzofuran-3-carboxamide, pharmaceutical compositions and the methods of preparation and the use thereof. |
| Inventor(s): | Zhenping Wu, Wenji Li, Yuping CHU |
| Assignee: | Hutchmed Ltd |
| Application Number: | US16/678,760 |
|
Patent Claim Types: see list of patent claims | Use; Composition; |
Drugs Protected by US Patent 11,046,674
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Takeda Pharms Usa | FRUZAQLA | fruquintinib | CAPSULE;ORAL | 217564-001 | Nov 8, 2023 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | TREATMENT OF PATIENTS WITH METASTATIC COLORECTAL CANCER WHO HAVE BEEN PREVIOUSLY TREATED WITH FLUOROPYRIMIDINE-, OXALIPLATIN-, AND IRINOTECAN-BASED CHEMOTHERAPY, ANTI-VEGF THERAPY, AND, IF RAS WILD-TYPE AND MEDICALLY APPROPRIATE, ANTI-EGFR THERAPY | ⤷ Start Trial | ||||
| Takeda Pharms Usa | FRUZAQLA | fruquintinib | CAPSULE;ORAL | 217564-002 | Nov 8, 2023 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | TREATMENT OF PATIENTS WITH METASTATIC COLORECTAL CANCER WHO HAVE BEEN PREVIOUSLY TREATED WITH FLUOROPYRIMIDINE-, OXALIPLATIN-, AND IRINOTECAN-BASED CHEMOTHERAPY, ANTI-VEGF THERAPY, AND, IF RAS WILD-TYPE AND MEDICALLY APPROPRIATE, ANTI-EGFR THERAPY | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,046,674
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 3191475 | ⤷ Start Trial | CA 2024 00052 | Denmark | ⤷ Start Trial |
| European Patent Office | 3191475 | ⤷ Start Trial | PA2024541 | Lithuania | ⤷ Start Trial |
| European Patent Office | 3191475 | ⤷ Start Trial | 301307 | Netherlands | ⤷ Start Trial |
| European Patent Office | 3191475 | ⤷ Start Trial | LUC00372 | Luxembourg | ⤷ Start Trial |
| European Patent Office | 3191475 | ⤷ Start Trial | CR 2024 00052 | Denmark | ⤷ Start Trial |
| European Patent Office | 3191475 | ⤷ Start Trial | 122024000069 | Germany | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
